CA2859287A1 - Reconstitution method for high concentration dry protein formulations - Google Patents
Reconstitution method for high concentration dry protein formulations Download PDFInfo
- Publication number
- CA2859287A1 CA2859287A1 CA2859287A CA2859287A CA2859287A1 CA 2859287 A1 CA2859287 A1 CA 2859287A1 CA 2859287 A CA2859287 A CA 2859287A CA 2859287 A CA2859287 A CA 2859287A CA 2859287 A1 CA2859287 A1 CA 2859287A1
- Authority
- CA
- Canada
- Prior art keywords
- reconstitution
- dry
- protein
- vessel
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 241
- 238000009472 formulation Methods 0.000 title claims abstract description 207
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 145
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 145
- 238000003168 reconstitution method Methods 0.000 title description 23
- 238000000034 method Methods 0.000 claims abstract description 134
- 239000000243 solution Substances 0.000 claims description 105
- 239000003085 diluting agent Substances 0.000 claims description 87
- 239000006260 foam Substances 0.000 claims description 57
- 238000005119 centrifugation Methods 0.000 claims description 54
- 239000012460 protein solution Substances 0.000 claims description 32
- 238000012546 transfer Methods 0.000 claims description 24
- 238000005187 foaming Methods 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 18
- 230000002829 reductive effect Effects 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 description 44
- 239000000843 powder Substances 0.000 description 39
- 230000001225 therapeutic effect Effects 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000002085 persistent effect Effects 0.000 description 17
- 230000009467 reduction Effects 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000001035 drying Methods 0.000 description 8
- 230000009977 dual effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 239000012905 visible particle Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229920001222 biopolymer Polymers 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010032976 Enfuvirtide Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012906 subvisible particle Substances 0.000 description 3
- 229940074409 trehalose dihydrate Drugs 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002062 enfuvirtide Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229940099052 fuzeon Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940036185 synagis Drugs 0.000 description 2
- 229940099073 xolair Drugs 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940071829 ilaris Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Degasification And Air Bubble Elimination (AREA)
- Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1122430.0 | 2011-12-23 | ||
| GBGB1122430.0A GB201122430D0 (en) | 2011-12-23 | 2011-12-23 | Reconstitution method for high concentration dry protein formulation |
| PCT/GB2012/053266 WO2013093525A1 (en) | 2011-12-23 | 2012-12-24 | Reconstitution method for high concentration dry protein formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2859287A1 true CA2859287A1 (en) | 2013-06-27 |
Family
ID=45695059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859287A Abandoned CA2859287A1 (en) | 2011-12-23 | 2012-12-24 | Reconstitution method for high concentration dry protein formulations |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140308293A1 (enExample) |
| EP (1) | EP2793852A1 (enExample) |
| JP (1) | JP2015511129A (enExample) |
| BR (1) | BR112014015605A2 (enExample) |
| CA (1) | CA2859287A1 (enExample) |
| GB (1) | GB201122430D0 (enExample) |
| IN (1) | IN2014MN01381A (enExample) |
| WO (1) | WO2013093525A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201313368D0 (en) | 2013-07-26 | 2013-09-11 | Xstalbio Ltd | Novel Reconstitution devices |
| US20170274012A1 (en) * | 2014-09-03 | 2017-09-28 | Entegrion, Inc. | Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads |
| US10143625B2 (en) | 2015-03-17 | 2018-12-04 | Recon Therapeutics, Inc. | Pharmaceutical reconstitution |
| CN118085011A (zh) | 2016-08-17 | 2024-05-28 | 勃林格殷格翰国际公司 | 制备含有生物分子的高度浓缩的液体制剂的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178884A (en) * | 1988-05-18 | 1993-01-12 | Cryopharm Corporation | Lyophilized and reconstituted red blood cell compositions |
| DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
| DE10211227A1 (de) * | 2002-03-13 | 2003-10-02 | Aventis Behring Gmbh | Verfahren zur Rekonstitution von Iyophilisierten Proteinen |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| EP1958618A1 (de) * | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
| WO2011017070A1 (en) | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
-
2011
- 2011-12-23 GB GBGB1122430.0A patent/GB201122430D0/en not_active Ceased
-
2012
- 2012-12-24 IN IN1381MUN2014 patent/IN2014MN01381A/en unknown
- 2012-12-24 BR BR112014015605A patent/BR112014015605A2/pt not_active IP Right Cessation
- 2012-12-24 EP EP12813947.4A patent/EP2793852A1/en not_active Withdrawn
- 2012-12-24 JP JP2014548210A patent/JP2015511129A/ja active Pending
- 2012-12-24 WO PCT/GB2012/053266 patent/WO2013093525A1/en not_active Ceased
- 2012-12-24 US US14/367,715 patent/US20140308293A1/en not_active Abandoned
- 2012-12-24 CA CA2859287A patent/CA2859287A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013093525A1 (en) | 2013-06-27 |
| EP2793852A1 (en) | 2014-10-29 |
| IN2014MN01381A (enExample) | 2015-04-17 |
| JP2015511129A (ja) | 2015-04-16 |
| GB201122430D0 (en) | 2012-02-08 |
| BR112014015605A2 (pt) | 2017-07-04 |
| US20140308293A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2793863T3 (en) | PROCEDURE FOR THE PREPARATION OF AMORPH PRECIPTATED PROTEIN PARTICLES | |
| AU2011223805B2 (en) | Concentrated protein formulations and uses thereof | |
| MX2014010776A (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
| WO2019064263A1 (en) | NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS | |
| KR102350284B1 (ko) | 초음파 전구체 제조 방법 | |
| US20180098936A1 (en) | Methods and compositions for injecting high concentration and/or high viscosity active agent solutions | |
| US8372798B2 (en) | High-concentration protein formulations and method of manufacture | |
| US20140308293A1 (en) | Reconstitution method for high concentration dry protein formulations | |
| KR20220008277A (ko) | 가스 충전된 미세소포 | |
| US20110155620A1 (en) | Rapid reconstitution for lyophilized-pharmaceutical suspensions | |
| CA3162569A1 (en) | Stable antibody formulation | |
| Shire et al. | High-concentration antibody formulations | |
| US20160158716A1 (en) | Novel reconstitution assembly | |
| AU2021305093A1 (en) | Stabilized formulations containing anti-CTLA-4 antibodies | |
| TW202135860A (zh) | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 | |
| Zhang | Process optimization of albumin-stabilized mitotane nanoparticle preparation by dual centrifugation and first lyophilization study | |
| US20220332849A1 (en) | Stabilized Formulations Containing Anti-MUC16 x Anti-CD3 Bispecific Antibodies | |
| CA3231500A1 (en) | Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof | |
| CN117320700A (zh) | 含有抗muc16 x抗cd3双特异性抗体的稳定制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20161228 |